The global Enteral Feeding Formulas market size is expected to be worth around US$ 10.3 billion by 2030, according to a new report by Vision Research Reports.
The global Enteral Feeding Formulas market size was valued at US$ 5.10 billion in 2020 and is anticipated to grow at a CAGR of 5.11% during forecast period 2021 to 2030.
Growth Factors
The growing prevalence of chronic diseases such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes is projected to drive the demand for products that support patients with oral intake issues. In addition, the rise in preterm births is one of the significant factors boosting the demand for enteral feeding formulas to meet the nutritional requirements of newborns.
Based on product, the standard formulas segment dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a vast variety of standard formulas coupled with increased demand for low-cost nutrient formulations. In addition, the demand with respect to standard tube feeds is significant among the volume-sensitive patients or the patients on fluid restrictions. Such conditions include renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
In 2020, based on flow type, the intermittent feeding flow type segment accounted for the highest revenue share in the market because intermittent feeding has shown better tolerance in patients as compared to bolus feeding. Moreover, this type of feeding does not require feeding pumps, which is helpful in allowing greater mobility in between the feedings. This is expected to increase its adoption among the hospital as well as homecare settings, thereby affirmatively impacting the segment growth.
In 2020, based on stage, the adults' segment accounted for the highest revenue share of 88.4% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The rising adoption of tube feeds in adults is one of the crucial factors driving the growth. In addition, the availability of large number of tube feeds or products for adults on a commercial level also contributes to the large share held by the segment. Glucerna, Osmolite, TwoCal, Vital, Promote, and Jevity are some of the popular brands by Abbott Nutrition for adults.
Based on indications, other indications, followed by cancer care accounted for the largest share in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote market growth. For instance, according to GLOBOCON 2020, there were around 19.3 million new cases of cancer worldwide in 2020. Europe accounted for about 23.4% of total cancer cases and Asia had the highest population suffering from cancer, which was about 60%.
In 2020, based on end user, the homecare segment accounted for the highest revenue share in the market and this segment is projected to witness the fastest CAGR over the forecast period. The increasing number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition is one of the key factors contributing to the growth of this segment. For instance, according to a recent survey conducted in the U.K., there were 187 patients on home enteral tube feeding out of the total 257 patients. This suggested that approximately 72% of patients were on home enteral tube feeding.
North America dominated the market with a revenue share of 29.7% in 2020 owing to the growing burden of chronic diseases such as diabetes, cancer, and other neurological conditions. Furthermore, increasing preference for home-based enteral therapy has decreased the number of patient visits to hospitals and clinics. In addition, increasing malnutrition is expected to further boost the demand for enteral feeding formulas in this region.
In addition, the rising number of COVID-19 cases in various geographies coupled with the large geriatric population, susceptible to various health conditions, are among the factors contributing to the growth of the market. For instance, according to an article published in Europe PMC in 2020, enteral nutrition is generally preferred over parenteral nutrition for COVID-19 patients admitted to the ICUs. In addition, it should be provided within 48 hours of admission. Hence, such instances signify increasing adoption of enteral feeding formulas during the pandemic.
Report Highlights
Based on product type, standard formulas dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a wide variety of standard formulas coupled with increased demand for low-cost nutrient formulations. In addition, the demand with respect to standard tube feeds is significant among the volume-sensitive patients or the patients on fluid restrictions. Such conditions include renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
In addition, the disease specific formulas segment is anticipated to grow at the fastest rate during the forecast period. The high prevalence of chronic diseases, such as cancer, diabetes, and liver failure, is propelling the demand for disease-specific formulas. In addition, recent product developments to cater to specific nutritional requirements of various diseases are expected to boost the demand in the coming years. NOVASOURCE RENAL by Nestlé Health Science and SUPLENA by Abbott are examples of standard tube feeds used in patients with Chronic Kidney Disease (CKD).
In 2020, based on flow type, intermittent feeding flow type accounted for the highest revenue share of 94.5% in the market. This is because intermittent feeding has shown better tolerance in patients as compared to bolus feeding. Moreover, this type of feeding does not require feeding pumps, which is helpful in allowing greater mobility in between the feedings. This is expected to increase its adoption among the hospital as well as homecare settings, thereby affirmatively impacting the segment growth.
In addition, the continuous feeding flow type segment is expected to witness the highest CAGR over the forecast period. The lower feeding rate of continuous feeding flow as compared to intermittent feeding is one of the major factors responsible for the lucrative growth of the segment. Continuous tube feeding is recommended for critically ill patients suffering from conditions such as respiratory failure, severe burns, and cancer. The increasing prevalence of such conditions is anticipated to propel the growth of the continuous feeding flow type segment during the forecast period.
In 2020, based on stage, the adults' segment accounted for the highest revenue share of 88.4% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The rising adoption of tube feeds in adults is one of the crucial factors driving the growth. In addition, the availability of large number of tube feeds or products for adults on a commercial level also contributes to the large share held by the segment. Glucerna, Osmolite, TwoCal, Vital, Promote, and Jevity are some of the popular brands by Abbott Nutrition for adults.
Furthermore, increasing demand for tube feeds among pregnant women is also one of the major factors driving the market for the adult segment. In addition, pregnant women frequently suffer from hyperemesis gravidarum, which is categorized by severe vomiting and nausea, which may lead to a deficiency of vital nutrients and dehydration. According to a research study conducted by Mount Mary University, enteral nutrition showed successful pregnancy outcomes in women suffering from hyperemesis gravidarum. Moreover, increasing demand for tube feeds among patients suffering from neurovascular disorders is positively impacting the market growth.
Based on indications, others' segment dominated the market and accounted for the largest revenue share of 42.7% in 2020. The segment is followed by cancer care, which accounted for a significant share of 24.0% in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote the growth of the segment. For instance, according to GLOBOCON 2020, there were around 19.3 million new cases of cancer worldwide in 2020. Europe accounted for about 23.4% of total cancer cases and Asia had the highest population suffering from cancer, which was about 60%.
Cancer weakens immunity and leads to loss of energy, which results in malnutrition in 40% to 80% of the cases. This affects the response to the treatment as well as increases treatment-related toxicity. Hence, to maintain nutrition and positive nitrogen balance, tube feeding is used, thereby fueling the market growth. Major players, such as Abbott Laboratories, provide liquid formulations that can be tube fed to cancer patients, to help maintain their nutrient balance. For instance, Jevity 1.5 Cal is prescription-based nutrition that is useful for cancer patients.
In 2020, based on end user, the homecare segment accounted for the highest revenue share of 56.1% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The increasing number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition is one of the key factors contributing to the growth of this segment. For instance, according to a recent survey conducted in the U.K., there were 187 patients on home enteral tube feeding out of the total 257 patients. This suggested that approximately 72% of patients were on home enteral tube feeding.
Furthermore, rising awareness regarding enteral feeding formulas among home-based healthcare patients and increasing government intervention for educating the patient population with regards to the utilization of enteral feeding systems or pumps are some of the other factors boosting segment growth.
North America dominated the enteral feeding formulas market and accounted for the largest revenue share of 29.7% in 2020 owing to the growing burden of chronic diseases such as diabetes, cancer, and other neurological conditions. Furthermore, increasing preference for home-based enteral therapy has decreased the number of patient visits to hospitals and clinics. In addition, increasing malnutrition is expected to further boost the demand for enteral feeding formulas in this region.
Furthermore, in Asia Pacific, the market is expected to exhibit lucrative growth over the forecast period. The increasing incidence of preterm births is one of the major factors that propel the regional demand. According to the World Health Organization (WHO), India, China, Nigeria, Pakistan, and Indonesia are among the top five countries with the largest number of preterm births. Factors such as increasing healthcare expenditure and recent improvements in healthcare infrastructure in many countries including China, Japan, India, and Singapore are anticipated to drive the market in the forthcoming years.
Key Players
Abbott
Danone SA
Fresenius Kabi
Nestlé
Victus, Inc.
Primus Pharmaceuticals, Inc.
Meiji Holdings. Co., Ltd.
Rickett Benckiser Group Plc.
Market Segmentation
Product Outlook
Standard formula
Disease-specific formula
Flow Type Outlook
Intermittent feeding flow
Continuous feeding flow
Stage Outlook
Adult
Pediatric
Indication Outlook
Alzheimer’s
Nutrition Deficiency
Cancer Care
Diabetes
Chronic Kidney Diseases
Orphan Diseases
Dysphagia
Pain Management
Malabsorption/GI Disorder/Diarrhea
Others
End-user Outlook
Hospitals
Cardiology
Neurology
Critical Care (ICU)
Oncology
Others
Home Care
Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
Italy
France
Spain
Russia
Asia Pacific
Australia
China
Japan
South Korea
India
Singapore
New Zealand
Latin America
Mexico
Brazil
Argentina
Middle East Africa
South Africa
Saudi Arabia
UAE
The Enteral Feeding Formulas market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Enteral Feeding Formulas market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Enteral Feeding Formulas market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Enteral Feeding Formulas market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Enteral Feeding Formulas market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Enteral Feeding Formulas capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Enteral Feeding Formulas by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Enteral Feeding Formulas market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Enteral Feeding Formulas market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Enteral Feeding Formulas market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Enteral Feeding Formulas industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Enteral Feeding Formulas market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Enteral Feeding Formulas market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Enteral Feeding Formulas market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Enteral Feeding Formulas market. These factors have benefited the growth of the global market for Enteral Feeding Formulas. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Enteral Feeding Formulas. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Enteral Feeding Formulas are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Enteral Feeding Formulas Market, By Product Type
7.1. Enteral Feeding Formulas Market, By Product Type, 2020-2030
7.1.1. Standard Formula
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Disease-specific Formula
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Enteral Feeding Formulas Market, By Flow Type
8.1. Enteral Feeding Formulas Market, By Flow Type, 2020-2030
8.1.1. Intermittent Feeding Flow
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Continuous Feeding Flow
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Enteral Feeding Formulas Market, By Stage Type
9.1. Enteral Feeding Formulas Market, By Stage Type, 2020-2030
9.1.1. Adults
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Pediatrics
9.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Enteral Feeding Formulas Market, By Indication Type
10.1. Enteral Feeding Formulas Market, By Indication Type, 2020-2030
10.1.1. Alzheimer’s
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Nutrition Deficiency
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Cancer Care
10.1.3.1. Market Revenue and Forecast (2016-2030)
10.1.4. Diabetes
10.1.4.1. Market Revenue and Forecast (2016-2030)
10.1.5. Chronic Kidney Diseases
10.1.5.1. Market Revenue and Forecast (2016-2030)
10.1.6. Orphan Diseases
10.1.6.1. Market Revenue and Forecast (2016-2030)
10.1.7. Dysphagia
10.1.7.1. Market Revenue and Forecast (2016-2030)
10.1.8. Pain Management
10.1.8.1. Market Revenue and Forecast (2016-2030)
10.1.9. Malabsorption/GI Disorder/Diarrhea
10.1.9.1. Market Revenue and Forecast (2016-2030)
10.1.10. Others
10.1.10.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Enteral Feeding Formulas Market, By End-use Type
11.1. Enteral Feeding Formulas Market, By End-use, 2020-2030
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2016-2030)
11.1.2. Home Care
11.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 12. Global Enteral Feeding Formulas Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, By Product (2016-2030)
12.1.2. Market Revenue and Forecast, By Flow (2016-2030)
12.1.3. Market Revenue and Forecast, By Stage (2016-2030)
12.1.4. Market Revenue and Forecast, By Indication (2016-2030)
12.1.5. Market Revenue and Forecast, By End-use (2016-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, By Product (2016-2030)
12.1.6.2. Market Revenue and Forecast, By Flow (2016-2030)
12.1.6.3. Market Revenue and Forecast, By Stage (2016-2030)
12.1.6.4. Market Revenue and Forecast, By Indication (2016-2030)
12.1.7. Market Revenue and Forecast, By End-use (2016-2030)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, By Product (2016-2030)
12.1.8.2. Market Revenue and Forecast, By Flow (2016-2030)
12.1.8.3. Market Revenue and Forecast, By Stage (2016-2030)
12.1.8.4. Market Revenue and Forecast, By Indication (2016-2030)
12.1.8.5. Market Revenue and Forecast, By End-use (2016-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, By Product (2016-2030)
12.2.2. Market Revenue and Forecast, By Flow (2016-2030)
12.2.3. Market Revenue and Forecast, By Stage (2016-2030)
12.2.4. Market Revenue and Forecast, By Indication (2016-2030)
12.2.5. Market Revenue and Forecast, By End-use (2016-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, By Product (2016-2030)
12.2.6.2. Market Revenue and Forecast, By Flow (2016-2030)
12.2.6.3. Market Revenue and Forecast, By Stage (2016-2030)
12.2.7. Market Revenue and Forecast, By Indication (2016-2030)
12.2.8. Market Revenue and Forecast, By End-use (2016-2030)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, By Product (2016-2030)
12.2.9.2. Market Revenue and Forecast, By Flow (2016-2030)
12.2.9.3. Market Revenue and Forecast, By Stage (2016-2030)
12.2.10. Market Revenue and Forecast, By Indication (2016-2030)
12.2.11. Market Revenue and Forecast, By End-use (2016-2030)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, By Product (2016-2030)
12.2.12.2. Market Revenue and Forecast, By Flow (2016-2030)
12.2.12.3. Market Revenue and Forecast, By Stage (2016-2030)
12.2.12.4. Market Revenue and Forecast, By Indication (2016-2030)
12.2.13. Market Revenue and Forecast, By End-use (2016-2030)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, By Product (2016-2030)
12.2.14.2. Market Revenue and Forecast, By Flow (2016-2030)
12.2.14.3. Market Revenue and Forecast, By Stage (2016-2030)
12.2.14.4. Market Revenue and Forecast, By Indication (2016-2030)
12.2.15. Market Revenue and Forecast, By End-use (2016-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, By Product (2016-2030)
12.3.2. Market Revenue and Forecast, By Flow (2016-2030)
12.3.3. Market Revenue and Forecast, By Stage (2016-2030)
12.3.4. Market Revenue and Forecast, By Indication (2016-2030)
12.3.5. Market Revenue and Forecast, By End-use (2016-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, By Product (2016-2030)
12.3.6.2. Market Revenue and Forecast, By Flow (2016-2030)
12.3.6.3. Market Revenue and Forecast, By Stage (2016-2030)
12.3.6.4. Market Revenue and Forecast, By Indication (2016-2030)
12.3.7. Market Revenue and Forecast, By End-use (2016-2030)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, By Product (2016-2030)
12.3.8.2. Market Revenue and Forecast, By Flow (2016-2030)
12.3.8.3. Market Revenue and Forecast, By Stage (2016-2030)
12.3.8.4. Market Revenue and Forecast, By Indication (2016-2030)
12.3.9. Market Revenue and Forecast, By End-use (2016-2030)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, By Product (2016-2030)
12.3.10.2. Market Revenue and Forecast, By Flow (2016-2030)
12.3.10.3. Market Revenue and Forecast, By Stage (2016-2030)
12.3.10.4. Market Revenue and Forecast, By Indication (2016-2030)
12.3.10.5. Market Revenue and Forecast, By End-use (2016-2030)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, By Product (2016-2030)
12.3.11.2. Market Revenue and Forecast, By Flow (2016-2030)
12.3.11.3. Market Revenue and Forecast, By Stage (2016-2030)
12.3.11.4. Market Revenue and Forecast, By Indication (2016-2030)
12.3.11.5. Market Revenue and Forecast, By End-use (2016-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, By Product (2016-2030)
12.4.2. Market Revenue and Forecast, By Flow (2016-2030)
12.4.3. Market Revenue and Forecast, By Stage (2016-2030)
12.4.4. Market Revenue and Forecast, By Indication (2016-2030)
12.4.5. Market Revenue and Forecast, By End-use (2016-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, By Product (2016-2030)
12.4.6.2. Market Revenue and Forecast, By Flow (2016-2030)
12.4.6.3. Market Revenue and Forecast, By Stage (2016-2030)
12.4.6.4. Market Revenue and Forecast, By Indication (2016-2030)
12.4.7. Market Revenue and Forecast, By End-use (2016-2030)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, By Product (2016-2030)
12.4.8.2. Market Revenue and Forecast, By Flow (2016-2030)
12.4.8.3. Market Revenue and Forecast, By Stage (2016-2030)
12.4.8.4. Market Revenue and Forecast, By Indication (2016-2030)
12.4.9. Market Revenue and Forecast, By End-use (2016-2030)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, By Product (2016-2030)
12.4.10.2. Market Revenue and Forecast, By Flow (2016-2030)
12.4.10.3. Market Revenue and Forecast, By Stage (2016-2030)
12.4.10.4. Market Revenue and Forecast, By Indication (2016-2030)
12.4.10.5. Market Revenue and Forecast, By End-use (2016-2030)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, By Product (2016-2030)
12.4.11.2. Market Revenue and Forecast, By Flow (2016-2030)
12.4.11.3. Market Revenue and Forecast, By Stage (2016-2030)
12.4.11.4. Market Revenue and Forecast, By Indication (2016-2030)
12.4.11.5. Market Revenue and Forecast, By End-use (2016-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, By Product (2016-2030)
12.5.2. Market Revenue and Forecast, By Flow (2016-2030)
12.5.3. Market Revenue and Forecast, By Stage (2016-2030)
12.5.4. Market Revenue and Forecast, By Indication (2016-2030)
12.5.5. Market Revenue and Forecast, By End-use (2016-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, By Product (2016-2030)
12.5.6.2. Market Revenue and Forecast, By Flow (2016-2030)
12.5.6.3. Market Revenue and Forecast, By Stage (2016-2030)
12.5.6.4. Market Revenue and Forecast, By Indication (2016-2030)
12.5.7. Market Revenue and Forecast, By End-use (2016-2030)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, By Product (2016-2030)
12.5.8.2. Market Revenue and Forecast, By Flow (2016-2030)
12.5.8.3. Market Revenue and Forecast, By Stage (2016-2030)
12.5.8.4. Market Revenue and Forecast, By Indication (2016-2030)
12.5.8.5. Market Revenue and Forecast, By End-use (2016-2030)
Chapter 13. Company Profiles
13.1. Danone (Nutricia)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Nestle Health Science
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Abbott Nutrition
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Primus Pharmaceuticals, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Mead Johnson & Company, LLC
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Fresenius Kabi AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Meiji Holdings Co., Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Victus
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
Glossary of Terms